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Abstract: Aim
Accurate lymph node staging is vital to inform optimum treatment decisions in patients
with oesophageal cancer. This study evaluates the accuracy of contemporary N-
staging and provides radiological-pathological correlation in patients with lymph node
metastases (LNMs) that were radiologically staged N0.
Materials and Methods
One hundred and twelve patients were included who underwent surgery alone (n=41)
or had neo-adjuvant therapy (n=71) between October 2010 and December 2015.
Contrast-enhanced CT (CECT), endoscopic ultrasound (EUS) and PET/CT N-stage
were compared to pathological N-stage [node-negative (N0) vs node-positive (N+)
groups].  Fifty LNMs from 15 patients pre-operatively staged as N0 were measured and
the maximum size recorded.
Results
Accuracy, sensitivity and specificity of N0 vs N+ disease with CECT, EUS and PET/CT
was 54.5%, 39.7% and 77.3%, 55.4%, 42.6% and 75.0%, and 57.1% 35.3% and
90.9%, respectively.  All modalities were more likely to under-stage nodal disease;
CECT (X2 32.890, df 1, p<0.001), EUS (X2 28.471, df 1, p<0.001) and PET/CT (X2
50.790, df 1, p<0.001).  PET/CT was more likely to under-stage nodal disease than
EUS (p=0.031).  Median LNM size was 3 mm, with 41 (82%) of LNMs measuring <6
mm and 22 (44%) classified as micro-metastases (≤2 mm).
Conclusion
This study has demonstrated poor N-staging accuracy in the modern era of radiological
staging.  Eighty-two percent of LNMs measured <6mm, making direct identification
extremely challenging on medical imaging. Future research should focus on
investigating and developing alternative surrogate markers to predict the likelihood of
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Dear Editor, 
 
On behalf of the authors, I wish to thank you for accepting our manuscript for 
publication in Clinical Radiology. 
 
Please find our responses to the reviewers’ comments below.  
 
Reviewer #1 
 
Major comments: none 
 
Minor comments: 
 
Page 5, line 80: It would be worth describing here the criteria used to define positive 
nodes at CT. 
 
A sentence describing the criteria used has been included. 
 
Page 6, line 108: which criteria do you adopted to define positive nodes at PET? 
Please state. 
 
Our criteria for defining positive lymph nodes on PET have been included. 
 
Figures: authors could add two figures showing 1) a true positive nodal case and 2) 
a false negative nodal case, each showing CT, ultrasound, PET and if possible 
pathology. 
 
We have included a single figure (Figure 1) showing CT, PET, fused PET/CT 
images and the pathology slide for a ‘false negative’ case. After discussion, 
we decided not to include a ‘true positive’ case. The authors felt this would 
take up valuable space without adding much value because the general 
radiological community are likely to recognise a pathological lymph node. 
 
 
Anonymous list of revisions
Reviewer #2 
 
1. the length of time between imaging and surgery/pathological assessment, which 
has an unknown impact on how severely the various imaging modalities 
understage. This is mentioned by the authors as a weakness and cannot be 
rectified; such is the nature of retrospective studies. 
 
This limitation has not been changed. 
 
2. The small proportion of pathological specimen available for retrospective 
analysis. This is not seem to be discussed by the authors as a weakness. It is a 
shame since the part of the manuscript dealing with size measurement of the 
proven metastases is very interesting, but the fact that it is only a small subgroup 
makes it less valuable. The authors should at least mention why this was and 
whether anything linked those specimen that could be analysed (as a smaller 
point in this section please explicitly state that node measurements represent 
long axis). 
 
We have expanded the discussion regarding the availability of resection 
specimens for analysis.  This can be found in the histopathological methods of 
the materials and methods section. 
 
We hope you find our responses satisfactory and accept the manuscript for 
publication. 
 
Kind Regards, 
 
The Authors. 
 
Abstract 
Aim 
Accurate lymph node staging is vital to inform optimum treatment decisions in 
patients with oesophageal cancer. This study evaluates the accuracy of 
contemporary N-staging and provides radiological-pathological correlation in patients 
with lymph node metastases (LNMs) that were radiologically staged N0. 
Materials and Methods 
One hundred and twelve patients were included who underwent surgery alone 
(n=41) or had neo-adjuvant therapy (n=71) between October 2010 and December 
2015.  Contrast-enhanced CT (CECT), endoscopic ultrasound (EUS) and PET/CT N-
stage were compared to pathological N-stage [node-negative (N0) vs node-positive 
(N+) groups].  Fifty LNMs from 15 patients pre-operatively staged as N0 were 
measured and the maximum size recorded. 
Results 
Accuracy, sensitivity and specificity of N0 vs N+ disease with CECT, EUS and 
PET/CT was 54.5%, 39.7% and 77.3%, 55.4%, 42.6% and 75.0%, and 57.1% 35.3% 
and 90.9%, respectively.  All modalities were more likely to under-stage nodal 
disease; CECT (X2 32.890, df 1, p<0.001), EUS (X2 28.471, df 1, p<0.001) and 
PET/CT (X2 50.790, df 1, p<0.001).  PET/CT was more likely to under-stage nodal 
Abstract
disease than EUS (p=0.031).  Median LNM size was 3 mm, with 41 (82%) of LNMs 
measuring <6 mm and 22 (44%) classified as micro-metastases (≤2 mm). 
Conclusion 
This study has demonstrated poor N-staging accuracy in the modern era of 
radiological staging.  Eighty-two percent of LNMs measured <6mm, making direct 
identification extremely challenging on medical imaging. Future research should 
focus on investigating and developing alternative surrogate markers to predict the 
likelihood of LNMs. 
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 3 
Introduction 4 
Contemporary radiological staging of oesophageal cancer (OC) involves a multi-5 
modality approach. In the UK, patients have initial contrast-enhanced computed 6 
tomography (CECT) of the thorax and abdomen following histological confirmation to 7 
assess the potential resectability of the tumour, or any distant metastatic disease 8 
which may preclude radical therapy.  9 
If the patient is deemed suitable for radical treatment, either in the form of definitive 10 
chemo-radiotherapy (dCRT) or surgery (+/- neo-adjuvant therapy), positron emission 11 
tomography combined with computed tomography (PET/CT) and endoscopic 12 
ultrasound (EUS) are performed for a more detailed assessment of disease stage. 13 
(1)  PET/CT has greater sensitivity for distant metastatic disease than CECT (2), 14 
whereas EUS is regarded as the ‘gold-standard’ investigation for defining T- and N-15 
stage, whilst also assisting surgical and radiotherapy planning. (3)   16 
This staging process is complex and time-consuming but necessary, because each 17 
modality has limitations for lymph node staging.  CECT provides anatomical 18 
information only, relies on size criteria and involves radiation.  PET/CT also involves 19 
radiation but provides additional functional metabolic data and improves the positive 20 
predictive value (PPV) of lymph node metastases (LNMs). (4)  The differentiation of 21 
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peri-tumoural LNMs from adjacent avid tumour can be challenging on PET images. 22 
(5)  This may increase ‘false-negative’ rates therefore under-staging the extent of 23 
nodal disease. EUS has better sensitivity compared to CECT and PET/CT due to its 24 
superior contrast resolution. 25 
The prognosis of OC is poor, with 5-year survival approximately 13%. (6)  Many 26 
patients present with advanced disease and the incidence is increasing. (7)  The 27 
presence of LNMs is a major prognostic indicator, therefore it is vital to stage nodal 28 
disease accurately. (8)  Accurate staging optimises management plans and provides 29 
the best chance of survival for patients with potentially curable disease. If the multi-30 
disciplinary team (MDT) decide upon surgical management and radiological staging 31 
is ≥T3 or ≥N1, two cycles of neo-adjuvant chemotherapy (NACT) are given prior to 32 
resection.  This is currently considered best practice in the UK, because overall 33 
survival was shown to improve compared to surgery alone. (9)    34 
Management decisions are influenced by results of lymph node assessment based 35 
on findings of radiological staging investigations.  Differentiation of node-negative 36 
(N0) from node-positive (N+) disease is important, because this should ensure that 37 
patients avoid unnecessary chemotherapy if over-staged, and are not denied 38 
potentially beneficial neo-adjuvant chemotherapy if under-staged.  39 
However, the existence of small LNMs (<6 mm), which cannot be directly visualised 40 
on any imaging modality, are likely to cause inaccurate staging and progress, with a 41 
subsequent detrimental effect on patient outcome. (10) 42 
 3 
Therefore, we aim to define the accuracy of CECT, EUS and PET/CT N-stage in the 43 
modern era of radiological OC staging.  We will also investigate the prevalence of 44 
micro-metastases and size of LNMs in patients radiologically staged N0 but 45 
pathologically node-positive (pN+), by providing radiological-pathological correlation. 46 
 4 
Materials and Methods 47 
This retrospective cohort study includes consecutive patients who underwent 48 
surgical resection of an oesophageal or gastro-oesophageal (GOJ) tumour, over a 5-49 
year period (November 2010 – December 2015) within a centralised service.  50 
Radiological and pathological staging data was obtained from the blinded database 51 
(blinded) following Regional Upper Gastrointestinal (GI) Cancer MDT discussion.  52 
Institutional Review Board (IRB) approval was granted (ref no. 14/WA/1208).  The 53 
requirement for informed consent was waived. 54 
Inclusion criteria were a previously untreated, biopsy-proven oesophageal or GOJ 55 
tumour in patients who underwent surgery alone, or had a poor Mandard tumour 56 
regression grade (TRG 4) or no response (TRG 5) following either NACT or neo-57 
adjuvant chemo-radiotherapy (NACRT). (11)  All patients had fully completed CECT, 58 
EUS and PET/CT staging investigations and were classified according to the 59 
International Union Against Cancer (UICC) Tumour Node Metastasis (TNM) 7th 60 
edition. (12)  All patients also had a full pathological N-stage (pN), also defined by 61 
the TNM 7th edition.    62 
Patients with tumours that showed complete pathological response (pCR, TRG 1) or 63 
tumours with some response (TRG 2 & 3) following NACT or NACRT were excluded 64 
because the final pathology is not likely to be representative of pre-operative status.  65 
Incomplete radiological staging investigations in particular, EUS examinations, in 66 
which the operator was unable to traverse a stenotic tumour in order to fully classify 67 
N-stage, were excluded.  Patients that underwent an ‘open-and-close’ procedure due 68 
to irresectable disease at the time of operation, were also excluded. 69 
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CECT Acquisition Protocol 70 
CECT was performed either in the host institution of the centralised service (blinded) 71 
or in local referring hospitals prior to surgery, according to Royal College of 72 
Radiologists guidelines. (1)  All CECT examinations were reviewed at the Regional 73 
Upper GI MDT, and deemed to be of a satisfactory technical standard. The 74 
technique used at the host institution is as follows: GE HD 750 Discovery 64-slice 75 
scanner (GE Healthcare, Pollards Wood, Buckinghamshire, UK); helical acquisition 76 
with collimation of 40mm, pitch 0.984:1 and tube rotation speed of 0.4 seconds; tube 77 
output of 120kVp with smart mA dose modulation between 60-600mA; slice 78 
thickness of 0.625mm; up to 500ml of water orally and 100-150mls of Niopam 300 79 
intravenously with bolus tracking.  Lymph nodes were considered involved on CECT 80 
if the short axis measurement was 1 cm or greater, located in the expected 81 
distribution of disease, round with loss of fatty hilum and demonstrated altered 82 
density or enhancement. 83 
EUS Protocol 84 
All EUS examinations were performed in 3 centres by 4 endosonographers.  At the 85 
host institution, an initial endoscopic examination was performed using a 9 mm 86 
diameter Olympus Paediatric gastroscope (Olympus, Southend, UK) to assess the 87 
degree of oesophageal luminal stenosis.  Patients with an estimated oesophageal 88 
luminal diameter <15 mm underwent examination using the smaller-diameter MH-89 
908 oesophagoprobe, and where there was no luminal stenosis, the standard UM-90 
2000 echoendoscope was used (Olympus, Southend, UK). The type of 91 
echoendoscope used was at the discretion of the endoscopist.  The primary 92 
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oesophageal tumour was assessed, together with an evaluation of peri-oesophageal 93 
and peri-gastric structures as described previously. (13)  The criteria for malignant 94 
lymphadenopathy specified a hypo-echoic pattern, spherical contour, distinct border, 95 
and short axis diameter of 6 mm or more.   96 
PET/CT Acquisition Protocol 97 
Patients were fasted for at least 6 hours prior to tracer administration. Serum glucose 98 
levels were routinely checked and confirmed to be less than 7.0 mmol/L prior to 99 
proceeding with imaging. Patients received a dose of 4 MBq of 18F-FDG per kilogram 100 
of body weight. Uptake time was 90 minutes, which is standard at our institution. 18F-101 
FDG PET/CT imaging was performed with a GE 690 PET/CT scanner (GE 102 
Healthcare, Pollards Wood, Buckinghamshire, UK). CT images were acquired in a 103 
helical acquisition with a pitch of 0.98 and a tube rotation speed of 0.5 seconds. 104 
Tube output was 120 kVp with output modulation between 20 and 200 mA. Matrix 105 
size for the CT acquisition was 512 x 512 pixels with a 50cm field of view. No oral or 106 
intravenous contrast was administered.  PET images were acquired at 3 minutes per 107 
field of view. The length of the axial field of view was 15.7 cm. Images were 108 
reconstructed with the ordered subset expectation maximisation algorithm, with 24 109 
subsets and 2 iterations. Matrix size was 256 x 256 pixels, using the VUE Point ™ 110 
time of flight algorithm.  Nodes were classed as involved on PET/CT if identified on 111 
the CT component and showed FDG-uptake appreciably higher than background 112 
values.  No specific standardised uptake value was used for the inclusion of regional 113 
nodes.  Lymph nodes considered physiological or related to an alternative aetiology 114 
were excluded from the N-stage.  115 
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Histopathological Methods 116 
Histopathological reporting of OC specimens was performed according to minimum 117 
requirements defined by the Royal College of Pathologists (RCPath). (14)  All lymph 118 
nodes identified in the resection specimen were prepared in 3 mm slices for 119 
pathological evaluation.  N-stage was then assigned depending on the number of 120 
LNMs identified.  TRG of the primary tumour was assigned according to the degree 121 
of fibrosis compared to residual tumour cells. (11)  In discordant cases, all available 122 
resection specimens that were radiologically staged N0 but pathologically N+ were 123 
further evaluated.  All available specimens were retrieved and reviewed from the 124 
archive.  Due to the retrospective nature of analysis, some of the older cases were 125 
archived off-site, and were unavailable at the time of evaluation. The maximum size 126 
(long axis) of both involved lymph nodes and metastases within those lymph nodes, 127 
were retrospectively recorded.  Maximum size was defined as the largest dimension 128 
on the glass slide measured by a Consultant Pathologist.  A micro-metastasis is 129 
defined as tumour deposit measuring ≤2 mm. (15)  Furthermore, a metastasis to 130 
lymph node ratio was calculated. 131 
Statistical Analysis 132 
Descriptive statistics are used to describe categorical and continuous variables.  In 133 
this study, N-stage is separated into negative (N0) and N+ (N1, N2 or N3) groups.  134 
Accuracy is defined as number of correct investigations divided by total number of 135 
investigations. Sensitivity and specificity of N+ disease are calculated for each 136 
modality.  A Chi-square test assessed significant differences in under- or over-137 
staging for each modality.  Significant differences in under-staging between 138 
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modalities was assessed with McNemar’s test.  A p-value <0.05 was considered 139 
statistically significant.  Statistical analysis was performed with SPSS v23 (IBM, 140 
Chicago, IL). 141 
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Results 142 
A total of 190 patients were considered for inclusion in the study.  Seventy-eight 143 
patients (41.1%) were excluded from the study; 22 were ‘open-and-close’ 144 
procedures, 16 were TRG 1, 13 were TRG 2, 13 were TRG 3 following neo-adjuvant 145 
treatment, and 14 had incomplete EUS staging. 146 
Following exclusions, 112 patients were included in the study.  The median age was 147 
65 years (range 24-78) and the male: female ratio was 92 (82.1%): 20 (17.9%).  148 
Fifty-nine tumours (52.7%) were located in the oesophagus; 10 in the mid 149 
oesophagus and 49 in the distal oesophagus.  Fifty-three tumours (47.3%) were 150 
located at the GOJ; 19 Siewert (Sw) type I, 15 Sw type II and 19 Sw type III. 151 
One hundred tumours (89.3%) were adenocarcinoma, with 11 SCC (9.8%) and 1 152 
neuroendocrine (0.9%).  Forty-one patients (36.6%) were treated with surgery alone, 153 
67 (59.8%) treated with NACT and 4 (3.6%) treated with NACRT.  Of the 71 treated 154 
with neo-adjuvant therapy, 42 were TRG 4 and 29 were TRG 5. 155 
For CECT, 75 patients (67.0%) were staged N0 and 37 (33.0%) were N+.  For EUS, 156 
72 patients (64.3%) were staged N0 and 40 (35.7%) were N+.  For PET/CT, 84 157 
(75.1%) were staged N0 and 28 (24.9%) were staged N+. Table 1 compares the 158 
frequency of radiological and pathological N-stages for CECT, EUS and PET/CT. 159 
Overall, median time between radiological staging and surgery was 3 months (range 160 
1-9 months), 1 month (range 0-3 months) in patients undergoing surgery alone and 4 161 
months (range 3-4 months) in patients receiving NACT. 162 
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 163 
Accuracy, Sensitivity and Specificity of CECT, EUS and PET/CT N-stage 164 
N0 vs N+ disease was correctly identified with CECT, EUS and PET/CT in 61 cases 165 
(54.5%), 62 (55.4%) and 64 (57.1%), respectively.  There was no significant 166 
difference between CECT, EUS and PET/CT for detecting N+ disease (X2 0.169, df 167 
2, p=0.919). The sensitivity and specificity for identifying N0 vs N+ disease with 168 
CECT, EUS and PET/CT was 39.7% and 77.3%, 42.6% and 75.0%, and 35.3% and 169 
90.9%, respectively. 170 
Under-staging vs Over-staging 171 
All modalities were significantly more likely to under-stage nodal disease; CECT (X2 172 
32.890, df 1, p<0.001), EUS (X2 28.471, df 1, p<0.001) and PET/CT (X2 50.790, df 1, 173 
p<0.001).  Comparing modalities, there was a borderline significant difference in 174 
under-staging between CECT and EUS (p=0.063) but no difference between CECT 175 
and PET/CT (p=1.000). However, there was a statistically significant between both 176 
EUS with PET/CT (p=0.031), suggesting PET/CT may further under-stage nodal 177 
disease. 178 
Pathological Lymph Node Measurement 179 
Fifteen archived resection specimens in patients pre-operatively staged N0 were 180 
available for retrospective measurement of the lymph nodes and their respective 181 
metastases. In total, 50 involved lymph nodes were assessed. (Table 2) The median 182 
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size of involved lymph nodes was 6 mm (range 2-15 mm) and the median metastasis 183 
size was 3 mm (0.5-13.5 mm).  Twenty-two (44%) LNMs measured ≤2 mm, which 184 
are defined as micro-metastases. (Fig. 1)   Forty-one (82%) LNMs were ≤6 mm and 185 
46 (92%) LNMs were ≤10 mm.  A metastasis to lymph node size ratio was 186 
calculated.  Thirty-one (62%) of the lymph nodes examined were replaced with ≥50% 187 
metastatic deposit, 19 (38%) were replaced with <50% metastatic deposit, with 12 188 
(24%) replaced with <25% metastatic deposit, using maximum size criteria. 189 
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Discussion 190 
This study has found poor N-stage accuracy with CECT, EUS and PET/CT. In 191 
general, all modalities were more likely to under-stage nodal disease, with PET/CT 192 
more likely to under-stage than EUS.  Another important finding, is the prevalence of 193 
small LNMs (<6 mm) in the resection specimens of patients radiologically staged N0.  194 
Micro-metastases have been found in lymph nodes of early oesophageal tumours 195 
(16) but little has been published with radiological correlation.  Studies investigating 196 
lung cancer have detected micro-metastases in patients radiologically staged N0 197 
(17), although evidence in OC is lacking.  198 
The majority of LNMs (82%) were <6 mm, which makes direct visualisation 199 
extremely challenging on current medical imaging techniques and is likely to be the 200 
main reason for discrepancy between radiological and pathological staging.  In 201 
addition, traditional radiological measurement of lymph nodes is taken in the short-202 
axis (18), which further reduces the likelihood that LNMs are diagnosed.  Even with 203 
the improved contrast resolution of EUS compared to cross-sectional imaging, it is 204 
unlikely that a lymph node of this size would confidently be classified as involved. 205 
(13)  Similarly, there was a relatively high prevalence of micro-metastases (44%). 206 
These results have significant implications for treatment decision-making processes 207 
and demonstrate that contemporary radiology techniques are inadequate for N-208 
staging. Numerous studies have demonstrated the importance of LNMs, which have 209 
a significant effect on overall survival. (8)  Better evidence is required to understand 210 
the prognostic significance of micro-metastases, but they are generally felt to confer 211 
a worse prognosis. (19, 20) 212 
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There is evidence that a significant proportion of surgical patients have systemic 213 
micro-metastases at the time of resection.  In one study, micro-metastases were 214 
detected in the resected rib in 53.7% to 78% of cases, and was dependent on the 215 
histological technique used. (21)  This is a higher detection rate than our study, but 216 
the results are comparable due to different techniques and tissues used between the 217 
studies.  The high rate of micro-metastases may be a reason that our results show 218 
significant under-staging of nodal disease, and perhaps clinicians could consider 219 
lowering the threshold for treating patients with systemic neo-adjuvant therapy. 220 
Previously published research from our institution has shown the prognostic 221 
significance of N-stage, LNM count and volume of nodal disease in patients with OC. 222 
(22, 23)  Nodal disease in these studies probably continues to be an important 223 
prognostic indicator, but the radiological staging is likely to have under-estimated the 224 
total nodal disease burden in those patient cohorts.  Results of staging performance 225 
have also been published from our institution.  These studies compared CECT and 226 
EUS with pN-staging.  Blackshaw et al focused on accuracy of N-staging in GOJ 227 
tumours and found significant differences in agreement, sensitivity and specificity 228 
between Siewert type II and type III tumours. (24)  Weaver et al found agreement, 229 
sensitivity and specificity of N-staging was 0.603, 79% and 84% for CECT and 230 
0.610, 91% and 68% for EUS. (13)  The results of the current study show poorer 231 
agreement and sensitivity. There are a number of reasons for these findings, 232 
including disease evolution, greater inter-observer variability between reporters, and 233 
fewer, but more specialised upper GI cancer pathologists reporting the resection 234 
specimens, with possibly higher rates of LNM detection. (15)  235 
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Accuracy of diagnosing N+ disease with CECT, EUS and PET/CT was 54.5%, 236 
55.4% and 57.1%, respectively.  In a clinical context, these results are unsatisfactory 237 
given that the presence of LNMs is such a major prognostic indicator. (8)  The 238 
sensitivity and specificity for identifying N0 vs N+ disease with CECT, EUS and 239 
PET/CT was 39.7% and 77.3%, 42.6% and 75.0%, and 35.3% and 90.9%.  240 
Specificity results are comparable with past meta-analyses but sensitivity results are 241 
lower for all modalities.  Previously published literature states sensitivity for N-242 
staging of EUS, CECT and PET/CT is 80%, 50 % and 57%, and specificity is 70%, 243 
83% and 85%, respectively. (2)  However, this meta-analysis was conducted prior to 244 
this centralisation of many upper GI cancer services.  The reduced sensitivity of 245 
staging investigations is supported by our results, which demonstrate that under-246 
staging is more common for all modalities. 247 
As current investigations are unreliable for differentiating N0 from N+ disease, future 248 
research should focus on investigating and developing new methods of predicting 249 
the likelihood of lymph node involvement.  Surrogate markers of LNMs, such as 250 
texture analysis of the primary tumour and other non-invasive quantitative imaging 251 
techniques, may allow better risk stratification of patients, provide more powerful 252 
prognostic data and further inform optimum treatment decisions. (25, 26)  MRI may 253 
provide an alternative staging modality.  Research studies have demonstrated 254 
variable diagnostic ability, with sensitivity, specificity and accuracy ranging between 255 
38-62%, 68-85% and 64-77%, respectively.  These current results are comparable to 256 
CT, EUS and PET/CT but continuing improvements in functional MRI scanner 257 
technology may yield further developments. (27, 28) 258 
Strengths of Study 259 
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This study provides radiological-pathological correlation in a group of OC patients 260 
with discordant nodal staging.  Radiological-pathological correlation is essential for 261 
understanding limitations of staging techniques and identifies areas requiring further 262 
research.  All patients were discussed at the Regional MDT and the management 263 
plan for each individual was decided upon by consensus. The Regional MDT covers 264 
a large population of over 1.4 million people and is highly experienced in the 265 
management of OC.  Histopathological examination was performed by consultant GI 266 
pathologists according the guidelines defined by the RCPath. (14)  We implemented 267 
strict criteria to control the selection of patients for this study, which compares 268 
imaging findings to ‘gold-standard’ pathological staging.  The majority of patients 269 
received neo-adjuvant therapy, which can alter the stage of disease between pre-270 
treatment imaging and surgical resection.  To control for this, only patients with 271 
Mandard TRG 4 or 5 were included, which should allow a more direct comparison 272 
with the final pathological resection specimen.  The majority of patients tend to have 273 
a TRG 4 or 5 response. (29) 274 
Limitations 275 
As a result of neo-adjuvant therapy, there is a time-lag between radiological staging 276 
and surgical resection, which could allow for tumour progression and LNM 277 
development.  However, the median time period in this study was 3 months. In 278 
addition, patients with an ‘open-and-close’ procedure were excluded, which further 279 
demonstrates radiological disease under-staging.  There are also known limitations 280 
of pathological lymph node examination. Approximately 3 mm sections are taken 281 
through lymph nodes once they are mounted in a cassette, but this may be 282 
performed with varying skill and consistency.  Micro-metastases may be missed if 283 
 16 
not bisected during preparation, and this suggests that the true incidence of micro-284 
metastases in this cohort of patients may be even greater.  Although the RCPath 285 
define the minimum requirements for pathological reporting, there is no 286 
recommended, standardised method for lymph node preparation and assessment in 287 
OC, at present.  The centralised upper GI cancer service is referred patients from 288 
several local NHS trusts.  As a result, multiple readers from different hospitals report 289 
the staging CECT examinations.  During this period, 3 endosonographers performed 290 
the EUS examinations in 2 different hospitals.  All PET/CT scans were performed 291 
using the same scanner and protocol and were reported by 4 different consultant 292 
radiologists.  However, all staging was performed according to the TNM 7th edition. 293 
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Conclusion 294 
In conclusion, this evaluation of contemporary staging performance over a 5-year 295 
period in a centralised upper GI cancer service has shown poor N-staging accuracy 296 
for CECT, EUS and PET/CT.  Radiological-pathological correlation in patients staged 297 
N0 has shown a large number of small LNMs (<6 mm) that are extremely 298 
challenging to diagnose directly from medical imaging.  The findings of this study 299 
have significant implications for patient care, because radiological staging results 300 
largely influence treatment decisions made by the MDT.  Future research should 301 
focus on prediction of the likelihood of lymph node involvement as current lymph 302 
node imaging is inadequate. 303 
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Figure Legends 396 
Figure 1. CT (with calipers), PET and fused PET/CT images of a ‘false-negative’ left 397 
gastric lymph node in a patient with junctional adenocarcinoma.  A low-power 398 
magnification of the lymph node shows a micro-metastasis.  For reference, the 399 
lymph node measured 5 mm in maximum size and the micro-metastasis (highlighted 400 
with yellow outline) measured 1.2 mm.401 
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Table 1 402 
Table 1. Comparison of N-stage frequency classified by CECT, EUS, PET/CT and 403 
pathology. 404 
CECT N-stage 
Frequency (%) N0 N1 N2 N3 Total 
pN0 34 (30.4) 8 (7.1) 2 (1.7) 0 (0.0) 44 (39.3) 
pN1 21 (18.8) 4 (3.6) 2 (1.7) 0 (0.0) 27 (24.1) 
pN2 16 (14.3) 10 (8.9) 1 (0.9) 0 (0.0) 27 (24.1) 
pN3 4 (3.6) 7 (6.3) 3 (2.7) 0 (0.0) 14 (12.5) 
Total 75 (67.0) 29 (25.9) 8 (7.1) 0 (0.0) 112 (100.0) 
EUS N-Stage 
Frequency (%) N0 N1 N2 N3 Total 
pN0 33 (29.5) 9 (8.0) 1 (0.9) 1 (0.9) 44 (39.3) 
pN1 20 (17.9) 7 (6.3) 0 (0.0) 0 (0.0) 27 (24.1) 
pN2 13 (11.6) 10 (8.9) 4 (3.6) 0 (0.0) 27 (24.1) 
pN3 6 (5.4) 6 (5.4) 1 (0.9) 1 (0.9) 14 (12.5) 
Total 72 (64.3) 32 (28.6) 6 (5.4) 2 (1.7) 112 (100.0) 
PET/CT N-stage 
Frequency (%) N0 N1 N2 N3 Total 
pN0 40 (35.8) 4 (3.6) 0 (0.0) 0 (0.0) 44 (39.4) 
pN1 23 (20.5) 4 (3.6) 0 (0.0) 0 (0.0) 27 (24.1) 
pN2 15 (13.4) 10 (8.9) 2 (1.7) 0 (0.0) 27 (24.1) 
pN3 6 (5.4) 6 (5.4) 2 (1.7) 0 (0.0) 14 (12.5) 
Total 84 (75.1) 24 (21.4) 4 (3.6) 0 (0.0) 112 (100.0) 
 405 
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Table 2 406 
Table 2. Frequency of and distribution of lymph node and metastasis size when 407 
separated in groups of 2 mm for descriptive purposes. 408 
Frequency 
(%) 
Maximum Size (mm) 
0-2 2.1-4 4.1-6 6.1-8 8.1-10 10.1-12 12.1-14 14.1-16 
Lymph Node 3 (6.0) 11 (22.0) 13 (26.0) 12 (24.0) 4 (8.0) 3 (6.0) 3 (6.0) 1 (2.0) 
Metastasis 22 (44.0) 9 (18.0) 10 (20.0) 3 (6.0) 2 (4.0) 2 (4.0) 2 (4.0) 0 (0.0) 
 409 
Revised Figure Click here to download Revised Figure Figure1_1200dpi.tiff 
Highlights 
1. CT, EUS and PET/CT N-staging accuracy is poor in oesophageal cancer.   
2. CT, EUS and PET/CT are all more likely to under-stage nodal disease. 
3. Many lymph node metastases are too small to be identified with direct imaging. 
 
Highlights
